Art. -Nr.: HY-P0187

Senktide

3 Cited Publications

Kundenbewertung

Based on 3 publication(s) in Google Scholar

Senktide is a potent, selective agonist of the neuromedin K3 (NK3) receptor (EC₅₀=0.5-3 nM). Senktide less potently agonizes the NK1 receptor (EC₅₀=35 µM). Senktide is promising for research of neurological disease.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.91%
CAS. Nr.: 106128-89-6
Formel: C₄₀H₅₅N₇O₁₁S
Molecular Weight:841.97

Speicherung:

Sealed storage, away from moisture.

Powder -80°C, 2 years , -20°C, 1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Senktide Chemical Structure

CAS. Nr.: 106128-89-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (3)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

NK3R

0.5-3 nM (EC₅₀)

NK1R

35 nM (EC₅₀)

Alle Neurokinin Receptor Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	EC₅₀	3 nM Compound: senktide	Activity at human NK3 receptor expressed in CHO cells assessed as increase in inositol phosphate generation Activity at human NK3 receptor expressed in CHO cells assessed as increase in inositol phosphate generation	[PMID: 16950617]
CHO	EC₅₀	0.011 μM Compound: Senktide	Agonist activity at human NK3R expressed in CHO cells assessed as potentiation of senktide-induced effect Agonist activity at human NK3R expressed in CHO cells assessed as potentiation of senktide-induced effect	[PMID: 25247671]
CHO	IC₅₀	0.056 μM Compound: Senktide	Displacement of [125I]His3, MePhe7 from human NK3R expressed in CHO cell membranes by scintillation counting Displacement of [125I]His3, MePhe7 from human NK3R expressed in CHO cell membranes by scintillation counting	[PMID: 25247671]
CHO	IC₅₀	11 nM Compound: SENKTIDE	Inhibitory activity against cloned human Tachykinin receptor 3 in CHO cells labeled with [125I][MePhe7]-NKB Inhibitory activity against cloned human Tachykinin receptor 3 in CHO cells labeled with [125I][MePhe7]-NKB	[PMID: 8648606]
CHO	EC₅₀	7 nM Compound: Senktide	Compound was evaluated for concentration-dependent and oscillatory increase in [Ca2+], caused by activation of hNK3 receptors in CHO cells Compound was evaluated for concentration-dependent and oscillatory increase in [Ca2+], caused by activation of hNK3 receptors in CHO cells	[PMID: 9871763]
CHO	IC₅₀	1 nM Compound: Senktide	Compound was evaluated for its ability to displace [3H]NKB binding in hNK3 receptors expressed in CHO cells Compound was evaluated for its ability to displace [3H]NKB binding in hNK3 receptors expressed in CHO cells	[PMID: 9871763]
CHO	IC₅₀	21 nM Compound: Senktide	Binding affinity towards human Tachykinin receptor 3 stably expressed in CHO cells using [125I][MePhe7]-NKB as radioligand Binding affinity towards human Tachykinin receptor 3 stably expressed in CHO cells using [125I][MePhe7]-NKB as radioligand	10.1016/0960-894X(95)00313-I
CHO	IC₅₀	21 nM Compound: Senktide	Displacement of [125I][MePhe]-NKB from human NK3 receptor expressed in CHO cells Displacement of [125I][MePhe]-NKB from human NK3 receptor expressed in CHO cells	10.1016/S0960-894X(00)80360-1
CHO	EC₅₀	19 pM Compound: Senktide	Agonist activity at goat NK3 receptor expressed in CHO cells assessed as calcium influx relative to 100 nM senktide Agonist activity at goat NK3 receptor expressed in CHO cells assessed as calcium influx relative to 100 nM senktide	10.1039/C4MD00514G
CHO	EC₅₀	23 pM Compound: Senktide	Agonist activity at rat NK3 receptor expressed in CHO cells assessed as calcium influx relative to 100 nM senktide Agonist activity at rat NK3 receptor expressed in CHO cells assessed as calcium influx relative to 100 nM senktide	10.1039/C4MD00514G
CHO	EC₅₀	3.4 pM Compound: Senktide	Agonist activity at human NK3 receptor expressed in CHO cells assessed as calcium influx relative to 100 nM senktide Agonist activity at human NK3 receptor expressed in CHO cells assessed as calcium influx relative to 100 nM senktide	10.1039/C4MD00514G
CHO	EC₅₀	610 pM Compound: Senktide	Agonist activity at cattle NK3 receptor expressed in CHO cells assessed as calcium influx relative to 100 nM senktide Agonist activity at cattle NK3 receptor expressed in CHO cells assessed as calcium influx relative to 100 nM senktide	10.1039/C4MD00514G
CHO	IC₅₀	>10000 nM Compound: Senktide	Displacement of [125I]-NKA from NK2 receptor (unknown origin) expressed in CHO cells by scintillation counter Displacement of [125I]-NKA from NK2 receptor (unknown origin) expressed in CHO cells by scintillation counter	10.1039/C4MD00514G
CHO	IC₅₀	29 nM Compound: Senktide	Displacement of ([125I]His3-MePhe7)-NKB from NK3 receptor (unknown origin) expressed in CHO cells by scintillation counter Displacement of ([125I]His3-MePhe7)-NKB from NK3 receptor (unknown origin) expressed in CHO cells by scintillation counter	10.1039/C4MD00514G
CHO	IC₅₀	>10000 nM Compound: Senktide	Displacement of [125I]-BH-SP from NK1 receptor (unknown origin) expressed in CHO cells by scintillation counter Displacement of [125I]-BH-SP from NK1 receptor (unknown origin) expressed in CHO cells by scintillation counter	10.1039/C4MD00514G
IM-9	IC₅₀	>10000 nM Compound: SENKTIDE	Inhibitory activity against Tachykinin receptor 1 in human lymphoma IM9 cells labeled with [125I]Bolton-Hunter substance P Inhibitory activity against Tachykinin receptor 1 in human lymphoma IM9 cells labeled with [125I]Bolton-Hunter substance P	[PMID: 8648606]

In Vitro

The selective NK₃ receptor agonist Senktide excites 24 of 31 dopaminergic neurons in the substantia nigra pars compacta in a concentration-dependent manner. The effective concentration range is between 3 to 3000 nm. The mean EC₅₀ for Senktide is 41.2±9 nm (n=5)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

I.c.v. injection of Senktide causes a dose-dependent increase in total distance traveled (F_6,72=6.344, P<0.001). This increase reaches statistical significance compare to the vehicle-treated group at 0.06 nmol and higher. The Senktide-induced increase in locomotor activity brought about by 0.1 nmol of Senktide is significantly and dose-dependently decreased by the tachykinin NK₃ receptor antagonists talnetant at 30 mg/kg and SB222200 at 30 mg/kg, but not by osanetant, when tested in parallel in a single experiment (F_7,78=10.32, P<0.001), although a non-significant reduction is observed. However, when tested using another vehicle (Vitamin E and glycofurol), osanetant does decrease activity significantly compare to Senktide-treated gerbils (F_2,30=10.10, P<0.001)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 106128-89-6
Appearance Solid
Molecular Weight 841.97
Formel C₄₀H₅₅N₇O₁₁S
Color White to off-white
Sequence

Suc-Asp-Phe-{Me-Phe}-Gly-Leu-Met-NH2
Sequence Shortening

Suc-DF-{Me-Phe}-GLM-NH2
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (3)

All

Sort by:

Journal Impact Factor

Neuron

Tachykinin signaling defines distinct populations of glia in the enteric nervous system. [Abstract]

2026 Jan 8:S0896-6273(25)00927-4. PMID: 41512855
Protein Cell

Senktide blocks aberrant RTN3 interactome to retard memory decline and tau pathology in social isolated Alzheimer's disease mice. [Abstract]

2024 Apr 1;15(4):261-284. PMID: 38011644
FASEB J

Neurokinin 3 receptor agonist senktide stimulates GnRH release in isolated hypogonadotropic hypogonadism mice. [Abstract]

2025 Mar 31;39(6):e70498. PMID: 40135619

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (118.77 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.1877 mL

5.9385 mL

11.8769 mL

5 mM

0.2375 mL

1.1877 mL

2.3754 mL

10 mM

0.1188 mL

0.5938 mL

1.1877 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (2.97 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (2.97 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (2.97 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Cell Assay^[2]

Experiments are performed on brain slices (300 μM thick) from 150 g male Wistar rats and extracellular recordings are made by conventional techniques. Drugs (including Senktide) are applied by bath perfusion and removal is achieved simply by returning to the control drug-free solution. Extracellular electrodes are filled with aCSF and have resistances of 5 to 14 MΩ. For intracellular recordings, electrodes are filled with 1 M potassium acetate and have d.c. resistances of 70 to 110 MΩ. Neurons are considered to be dopaminergic if they have a characteristic waveform, slow firing rate (~5 Hz) and inhibitory response to dopamine^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

For the Senktide dose-response curve, gerbils are first allowed to habituate to the test area for 30 min. Animals (n=10 to 12 per drug treatment group) are anesthetized with isoflurane, a small incision is made in the skin over bregma, and an injection of Senktide at 0.01, 0.03, 0.06, 0.1, 0.3 or 0.6 nmol in 5 μL of vehicle is placed i.c.v. using a syringe with a 4.5 mm long needle. Wounds are clipped shut, and animals allowed to awaken from anesthesia, then placed directly into the locomotor activity boxes and recording commenced. For testing of the NK₁ receptor antagonist aprepitant (1, 3 or 10 mg/kg p.o.), gerbils are first treated with aprepitant or vehicle (0.9% NaCl with 0.3% Tween80) and returned to the home cage for 90 min. Animals are then placed in the open field for 30 min of habituation. During the last 5 min of habituation, 0.03 nmol Senktide is injected i.c.v^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (286 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Nordquist RE, et al. The tachykinin NK3 receptor agonist senktide induces locomotor activity in male Mongolian gerbils. Eur J Pharmacol. 2008 Dec 14;600(1-3):87-92. [Content Brief]

[2]. Keegan KD, et al. The selective NK3 receptor agonist senktide excites a subpopulation of dopamine-sensitiveneurones in the rat substantia nigra pars compacta in vitro. Br J Pharmacol. 1992 Jan;105(1):3-5. [Content Brief]

[3]. Byk G, et al. Synthesis and biological activity of NK-1 selective, N-backbone cyclic analogs of the C-terminal hexapeptide of substance P. J Med Chem. 1996 Aug 2;39(16):3174-8. [Content Brief]

[4]. Sarau HM, et al. Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist. J Pharmacol Exp Ther. 1997 Jun;281(3):1303-11. [Content Brief]

[5]. Harrison T, et al. High affinity, selective neurokinin 2 and neurokinin 3 receptor antagonists from a common structural template. Bioorg Med Chem Lett. 1998 Jun 2;8(11):1343-8. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.1877 mL	5.9385 mL	11.8769 mL	29.6923 mL
	5 mM	0.2375 mL	1.1877 mL	2.3754 mL	5.9385 mL
	10 mM	0.1188 mL	0.5938 mL	1.1877 mL	2.9692 mL
	15 mM	0.0792 mL	0.3959 mL	0.7918 mL	1.9795 mL
	20 mM	0.0594 mL	0.2969 mL	0.5938 mL	1.4846 mL
	25 mM	0.0475 mL	0.2375 mL	0.4751 mL	1.1877 mL
	30 mM	0.0396 mL	0.1979 mL	0.3959 mL	0.9897 mL
	40 mM	0.0297 mL	0.1485 mL	0.2969 mL	0.7423 mL
	50 mM	0.0238 mL	0.1188 mL	0.2375 mL	0.5938 mL
	60 mM	0.0198 mL	0.0990 mL	0.1979 mL	0.4949 mL
	80 mM	0.0148 mL	0.0742 mL	0.1485 mL	0.3712 mL
	100 mM	0.0119 mL	0.0594 mL	0.1188 mL	0.2969 mL

Keywords

Senktide

3 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Senktide

Peptide Library

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Publications Citing Use of MedChemExpress (MCE) Senktide

Alle Neurokinin Receptor Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (3)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Senktide

Peptide Library

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Publications Citing Use of MedChemExpress (MCE) Senktide

Alle Neurokinin Receptor Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (3)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Senktide Related Classifications

HY-P0187 Related Classifications